Work

A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma

Year: 2020

Type: article

Study design: Clinical Trial

Source: Investigational New Drugs

DOI: 10.1007/s10637-020-00950-1

Authors: David A. Reardon, Annick Desjardins, Olivier Rixe, Timothy Cloughesy, Shilpa Alekar, Jason H. Williams, Ray Li, Carrie Turich Taylor, Andrew B. Lassman

Institutions: Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Duke Medical Center, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, Pfizer (United States), Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Pfizer, National Cancer Institute

Award: G814179290

OpenAlex ID: W3028368903

FWCI: 3.716

Cites: 24

Cited by: 61

Related to: 10